Skip to main content

A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 with Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Gastroenterology

Awarded By

COUR Pharmaceuticals Development Company

Start Date

July 13, 2022

End Date

July 17, 2025
 

Administered By

Medicine, Gastroenterology

Awarded By

COUR Pharmaceuticals Development Company

Start Date

July 13, 2022

End Date

July 17, 2025